iOnctura
Genève
About iOnctura
iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies by developing novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $127.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2024)
- Website: ionctura.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ionctura-60981 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.